These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 26208210)

  • 1. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
    Du Y; Zhang X; Tao Q; Chen S; Le W
    Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV2-neurturin (CERE-120) for Parkinson's disease.
    Hickey P; Stacy M
    Expert Opin Biol Ther; 2013 Jan; 13(1):137-45. PubMed ID: 23228025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges.
    Grote J; Patel N; Bates C; Parmar MS
    Neurol Sci; 2024 Oct; 45(10):4699-4710. PubMed ID: 38795270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned?
    Kordower JH
    Methods Mol Biol; 2016; 1382():485-90. PubMed ID: 26611606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies in Parkinson's disease.
    Jankovic J; Poewe W
    Curr Opin Neurol; 2012 Aug; 25(4):433-47. PubMed ID: 22691758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
    Tereshchenko J; Maddalena A; Bähr M; Kügler S
    Neurobiol Dis; 2014 May; 65():35-42. PubMed ID: 24440408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
    Kelly MJ; O'Keeffe GW; Sullivan AM
    Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
    Voutilainen MH; Arumäe U; Airavaara M; Saarma M
    FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease - A Focused Review.
    Singh A; Sen D
    Curr Gene Ther; 2016; 16(4):278-286. PubMed ID: 27487991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upcoming treatments in Parkinson's disease, including gene therapy.
    Rodnitzky RL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S37-40. PubMed ID: 22166449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.